Please assess the completion status of the following clinical trial:

Trial Title: Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically confirmed stage IIIA (only N2),~* dry IIIB previously untreated inoperable NSCLC,~* 18 to 75 years old,~* Karnofsky Performance Status (KPS) ≥ 80%,~* weight loss ≤ 10% within the previous 3 months,~* normal organ functions were eligible.~* at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.0) \[10\].~Exclusion Criteria:~* stages I, II, IIIA (excepted N2), IIIB with pleural effucion and stage IV,~* pregnant or breastfeeding women. Women of Childbearing Age: Women of childbearing potential should take reliable contraceptive measures~* Symptomatic Neuropathy \> grade 1,~* associated Pathology and/or not controled diseases(cardiac insuficiency, myocardial infarction within 3 months before the inclusion ; hypertension, arythmia or uncontroled hypercalcémia; infection requiering iv antibiotic administration within 2 weeks before inculion),~* other associated cancer with the exception of cervical carcinoma in situ or skin cancer baso-cellular correctely treated,~* Previous treatment with an other antineoplasic,~* Known hypersensibility to drugs with a similar chemical structure ti this studied.~* important malabsorbtion syndrom or disease of gastro-intestinal track,~* Participation to another clinical trial within 30 days before inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vinorelbine cisplatin radiotherapy (Type: EXPERIMENTAL): Induction period + radio chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).